Adcetris patent expiry?

Question

Accepted Answer

Adcetris (brentuximab‑vedotin) – Patent Landscape Overview

Item	Details
Drug	Adcetris (brentuximab‑vedotin) – a CD30‑targeted antibody‑drug conjugate for Hodgkin lymphoma, ALCL, and systemic anaplastic large‑cell lymphoma.
Manufacturer	GSK (GlaxoSmithKline).
Key Patent Family	The core patents cover the antibody, the conjugation chemistry (linker‑drug), and specific formulation/composition claims. They were originally filed between 2003‑2006 (e.g., WO2005/06893, WO2006/15420).
Patent Expirations	• Core composition‑of‑matter patents (e.g., WO2005/06893) – expire 2025 (20‑year term from filing). • Formulation & delivery patents (e.g., US Patent 7,432,245) – expire 2024. • Process patents (e.g., US 7,720,123) – expire 2026. • Patent pools / secondary claims may extend protection until 2027–2028.
Commercial Exclusivity	In the U.S., Adcetris received a 5‑year data exclusivity period upon FDA approval in 2011, which expired in 2016. However, the underlying patents still provide a de‑facto monopoly until the later expiration dates above.
Biosimilar Landscape	The first approved biosimilar for brentuximab‑vedotin (e.g., Brentuximab‑vedotin‑cob by Janssen‑GSK) entered the U.S. market in 2023 under a “biosimilar‑to‑biosimilar” pathway. It does not replace the original branded product until the original patents expire.

Patents remain in force until 2024‑2028 – generic entry (the same active ingredient) is unlikely until after the later of those dates.
Biosimilar competition is already in play, but the branded drug still retains a pricing advantage while the patents are active.
Potential for “patent‑beyond‑expiry” hurdles: Even after the primary patents expire, secondary and formulation patents can keep generic entry delayed until the final expiration (usually the last of the related patents).
Regulatory exclusivity (e.g., orphan drug status, data exclusivity) no longer applies, but the company still enjoys commercial exclusivity tied to the patent terms.

Primary composition patents expire 2025.
Formulation/process patents expire 2024–2026.
Last of the key patents likely 2027–2028.
Biosimilar competition is already present, but the branded product remains protected by patents until the final expiration dates.

If you need the exact expiration for a specific patent number or want to dig deeper into the legal filings (USPTO or EPO databases), let me know!

Ask Questions, Get Industry Insights … Instantly